logo
Loading...
Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease
Medicine and HealthNature Medicine

Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease

K. Kelly, A. J. C. Bloor, et al.

This clinical trial found that 60% of participants with steroid-resistant acute graft-versus-host disease survived after two years of treatment with iPS cell-derived mesenchymal stromal cells (CYP-001). Impressively, there were no serious adverse events or safety concerns reported, indicating that this innovative therapy is both safe and well-tolerated. This research was conducted by Kilian Kelly, Adrian J. C. Bloor, James E. Griffin, Rohini Radia, David T. Yeung, and John E. J. Rasko.... show more
Introduction
Literature Review
Methodology
Key Findings
Discussion
Conclusion
Limitations
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 22+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny